BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,908,884 | +7.2% | 1,258,317 | +6.5% | 0.00% | -50.0% |
| Q2 2023 | $8,314,106 | -40.5% | 1,180,981 | -29.5% | 0.00% | -33.3% |
| Q1 2023 | $13,971,226 | -46.0% | 1,675,207 | -25.6% | 0.00% | -57.1% |
| Q4 2022 | $25,864,899 | -8.2% | 2,253,040 | +0.8% | 0.01% | 0.0% |
| Q3 2022 | $28,168,000 | -5.8% | 2,235,529 | -20.9% | 0.01% | 0.0% |
| Q2 2022 | $29,897,000 | -52.5% | 2,825,776 | -27.0% | 0.01% | -30.0% |
| Q1 2022 | $62,922,000 | -55.4% | 3,869,751 | -62.0% | 0.01% | +100.0% |
| Q4 2021 | $141,084,000 | +115.5% | 10,186,568 | +123.6% | 0.01% | -44.4% |
| Q3 2021 | $65,467,000 | -12.6% | 4,555,842 | -3.9% | 0.01% | -10.0% |
| Q2 2021 | $74,938,000 | +85.6% | 4,739,950 | +19.4% | 0.01% | +66.7% |
| Q1 2021 | $40,374,000 | -5.0% | 3,969,845 | -30.4% | 0.01% | +100.0% |
| Q4 2020 | $42,492,000 | +443.7% | 5,703,566 | +150.7% | 0.00% | +200.0% |
| Q3 2020 | $7,815,000 | -30.0% | 2,274,963 | -3.0% | 0.00% | -66.7% |
| Q2 2020 | $11,172,000 | +838.8% | 2,344,587 | +294.3% | 0.00% | – |
| Q1 2020 | $1,190,000 | +55.1% | 594,567 | +167.6% | 0.00% | – |
| Q4 2019 | $767,000 | +12.5% | 222,225 | -6.6% | 0.00% | – |
| Q3 2019 | $682,000 | -94.9% | 237,988 | -93.2% | 0.00% | -100.0% |
| Q2 2019 | $13,346,000 | +230.2% | 3,520,914 | +609.0% | 0.00% | 0.0% |
| Q1 2019 | $4,042,000 | +348.1% | 496,600 | +344.2% | 0.00% | – |
| Q4 2018 | $902,000 | +20.4% | 111,800 | +13.8% | 0.00% | – |
| Q3 2018 | $749,000 | -32.8% | 98,200 | -49.5% | 0.00% | – |
| Q2 2018 | $1,114,000 | +0.5% | 194,300 | -16.4% | 0.00% | – |
| Q1 2018 | $1,108,000 | +59.2% | 232,300 | +64.1% | 0.00% | – |
| Q4 2017 | $696,000 | -73.5% | 141,600 | -71.7% | 0.00% | -100.0% |
| Q3 2017 | $2,624,000 | +192.2% | 500,723 | +210.2% | 0.00% | – |
| Q2 2017 | $898,000 | -81.4% | 161,400 | -72.0% | 0.00% | -100.0% |
| Q1 2017 | $4,837,000 | -47.6% | 575,789 | -60.5% | 0.00% | -50.0% |
| Q4 2016 | $9,231,000 | +263.3% | 1,458,316 | +153.0% | 0.00% | +300.0% |
| Q3 2016 | $2,541,000 | +425.0% | 576,301 | +238.3% | 0.00% | – |
| Q2 2016 | $484,000 | -5.5% | 170,340 | -5.9% | 0.00% | – |
| Q1 2016 | $512,000 | -93.7% | 181,014 | -76.9% | 0.00% | -100.0% |
| Q4 2015 | $8,091,000 | -15.2% | 783,960 | -6.4% | 0.00% | -20.0% |
| Q3 2015 | $9,545,000 | +24.7% | 837,240 | +63.3% | 0.01% | +66.7% |
| Q2 2015 | $7,657,000 | +58.9% | 512,828 | -3.9% | 0.00% | +50.0% |
| Q1 2015 | $4,820,000 | -38.0% | 533,714 | -16.5% | 0.00% | 0.0% |
| Q4 2014 | $7,769,000 | +26.9% | 638,926 | +2.1% | 0.00% | 0.0% |
| Q3 2014 | $6,122,000 | -30.8% | 626,000 | -9.8% | 0.00% | -50.0% |
| Q2 2014 | $8,846,000 | -52.1% | 693,742 | -60.2% | 0.00% | -50.0% |
| Q1 2014 | $18,460,000 | +141.0% | 1,744,767 | +73.1% | 0.01% | +166.7% |
| Q4 2013 | $7,661,000 | +94.8% | 1,007,900 | +86.6% | 0.00% | +50.0% |
| Q3 2013 | $3,932,000 | +493.1% | 540,200 | +26.2% | 0.00% | – |
| Q2 2013 | $663,000 | – | 428,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |